Advanced search
Publication Cover
mAbs Volume 5, 2013 - Issue 1
Submit an article Journal homepage
1,267
Views
13
CrossRef citations to date
0
Altmetric
Meeting Report

American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates

May 24, 2012, San Diego, CA

Karen Thudium Novartis Pharmaceuticals; Clinical Pharmacology; Oncology Business Unit; Florham Park, NJ USACorrespondence[email protected] [email protected]
,
Sanela Bilic Novartis Pharmaceuticals; Clinical Pharmacology; Oncology Business Unit; Florham Park, NJ USACorrespondence[email protected] [email protected]
,
Douglas Leipold Genentech; South San Francisco, CA USA
,
William Mallet Novartis Institutes for BioMedical Research; Emeryville, CA USA
,
Surinder Kaur Genentech; South San Francisco, CA USA
,
Bernd Meibohm The University of Tennessee Heath Science Center; College of Pharmacy; Memphis, TN USA
,
Hans Erickson ImmunoGen, Inc.; Waltham, MA USA
,
Jay Tibbitts Genentech; South San Francisco, CA USA
,
Hong Zhao U.S. Food and Drug Administration; Silver Spring, MD USA
&
Manish Gupta Bristol-Myers Squibb Company; New Brunswick, NJ USA
 show all
Pages 5-12 | Published online: 19 Dec 2012

References

  • Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?. MAbs 2011; 3:61 - 6; http://dx.doi.org/10.4161/mabs.3.1.13799; PMID: 20962582
  • Chudasama VL, Schaedeli Stark F, Harrold JM, Tibbitts J, Girish SR, Gupta M, et al. Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clin Pharmacol Ther 2012; 92:520 - 7; http://dx.doi.org/10.1038/clpt.2012.153; PMID: 22968044
  • Thon JN, Devine MT, Jurak Begonja A, Tibbitts J, Italiano JE Jr.. High-content live-cell imaging assay used to establish mechanism of trastuzumab emtansine (T-DM1)--mediated inhibition of platelet production. Blood 2012; 120:1975 - 84; http://dx.doi.org/10.1182/blood-2012-04-420968; PMID: 22665936
  • Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011; 29:398 - 405; http://dx.doi.org/10.1200/JCO.2010.29.5865; PMID: 21172893
  • Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010; 28:2698 - 704; http://dx.doi.org/10.1200/JCO.2009.26.2071; PMID: 20421541
  • Mahapatra KDW, Bumbaca D, Shen B. 2011. T-DM1-induced thrombocytopenia results from impaired platelet production in a HER2-independent manner. AACR-NCI-EORTC, ed., San Francisco, California: AACR.
  • Lin K, Tibbitts J. Pharmacokinetic considerations for antibody drug conjugates. Pharm Res 2012; 29:2354 - 66; http://dx.doi.org/10.1007/s11095-012-0800-y; PMID: 22740180
  • Bender BC, Schaedeli-Stark F, Koch R, Joshi A, Chu YW, Rugo H, et al. A population pharmacokinetic/pharmacodynamic model of thrombocytopenia characterizing the effect of trastuzumab emtansine (T-DM1) on platelet counts in patients with HER2-positive metastatic breast cancer. Cancer Chemother Pharmacol 2012; 70:591 - 601; http://dx.doi.org/10.1007/s00280-012-1934-7; PMID: 22886072
  • Shen BQ, Bumbaca D, Saad O, Yue Q, Pastuskovas CV, Khojasteh SC, et al. Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. Curr Drug Metab 2012; 13:901 - 10; http://dx.doi.org/10.2174/138920012802138598; PMID: 22475269
  • Girish S, Gupta M, Wang B, Lu D, Krop IE, Vogel CL, et al. Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer. Cancer Chemother Pharmacol 2012; 69:1229 - 40; http://dx.doi.org/10.1007/s00280-011-1817-3; PMID: 22271209
  • Lu D, Burris HA 3rd, Wang B, Dees EC, Cortes J, Joshi A, et al. Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer. Curr Drug Metab 2012; 13:911 - 22; http://dx.doi.org/10.2174/138920012802138688; PMID: 22475266

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.